These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 19581632)

  • 1. Comparison of side effects with 2 doses of the HIV drug efavirenz.
    Ann Intern Med; 2009 Aug; 151(3):I24. PubMed ID: 19581632
    [No Abstract]   [Full Text] [Related]  

  • 2. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial.
    Gutiérrez-Valencia A; Viciana P; Palacios R; Ruiz-Valderas R; Lozano F; Terrón A; Rivero A; López-Cortés LF;
    Ann Intern Med; 2009 Aug; 151(3):149-56. PubMed ID: 19581631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals.
    Poeta J; Linden R; Antunes MV; Real L; Menezes AM; Ribeiro JP; Sprinz E
    J Antimicrob Chemother; 2011 Nov; 66(11):2601-4. PubMed ID: 21890538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin.
    Mugusi S; Ngaimisi E; Janabi M; Mugusi F; Minzi O; Aris E; Bakari M; Bertilsson L; Burhenne J; Sandstrom E; Aklillu E
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1405-1415. PubMed ID: 30003275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summaries for patients. Neuropsychological side effects of efavirenz.
    Ann Intern Med; 2005 Nov; 143(10):I43. PubMed ID: 16287787
    [No Abstract]   [Full Text] [Related]  

  • 8. Efavirenz as a cause of ataxia in children.
    Hauptfleisch MP; Moore DP; Rodda JL
    S Afr Med J; 2015 Nov; 105(11):897-8. PubMed ID: 26632310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of the psychiatric side-effects of efavirenz.
    Kenedi CA; Goforth HW
    AIDS Behav; 2011 Nov; 15(8):1803-18. PubMed ID: 21484283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of amitriptyline to offset sleep disturbances caused by efavirenz.
    Koppel BS; Bharel C
    AIDS Patient Care STDS; 2005 Jul; 19(7):419-20. PubMed ID: 16053397
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
    Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
    Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symfi, Symfi Lo, and Cimduo for HIV.
    Med Lett Drugs Ther; 2019 Jan; 61(1563):e8-e10. PubMed ID: 30681663
    [No Abstract]   [Full Text] [Related]  

  • 13. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
    Leutscher PD; Stecher C; Storgaard M; Larsen CS
    Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are We Giving Optimal Dose of Efavirenz?
    Yunihastuti E
    Acta Med Indones; 2016 Jan; 48(1):1-2. PubMed ID: 27241537
    [No Abstract]   [Full Text] [Related]  

  • 15. Efavirenz dose reduction in HIV-infected patients: a long-term follow-up.
    Lanzafame M; Lattuada E; Cucchetto G; Concia E; Vento S
    AIDS; 2014 Nov; 28(18):2789-90. PubMed ID: 25493605
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
    Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
    Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenge of paediatric efavirenz dosing: implications and way forward for the sub-Saharan Africa.
    Mukonzo JK
    AIDS; 2014 Aug; 28(13):1855-7. PubMed ID: 25259700
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuropsychiatric reaction induced by abacavir.
    Colebunders R; Hilbrands R; De Roo A; Pelgrom J
    Am J Med; 2002 Nov; 113(7):616. PubMed ID: 12459415
    [No Abstract]   [Full Text] [Related]  

  • 20. No observable correlation between central nervous system side effects and EFV plasma concentrations in Japanese HIV type 1-infected patients treated with EFV containing HAART.
    Takahashi M; Ibe S; Kudaka Y; Okumura N; Hirano A; Suzuki T; Mamiya N; Hamaguchi M; Kaneda T
    AIDS Res Hum Retroviruses; 2007 Aug; 23(8):983-7. PubMed ID: 17725414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.